ACLX•benzinga•
Arcellx Announces New Data For Its iMMagine-1 Study In Patients With Relapsed And/Or Refractory Multiple Myeloma; Results From All 117 Patients Dosed In The Pivotal Phase 2 iMMagine-1 Study Of Anito-Cel Demonstrated 97% ORR And 68% CR/sCR At A Median Fol
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 14, 2025 by benzinga